$INCY

Stein Steven H sold $215K of INCY

Stein Steven H (CMO & Head of Late-Stage Dev.) sold 1,877 shares of INCYTE CORP (INCY) at $114.73 ($0.22M total) on 2026-07-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Stein Steven H
Published Jul 20, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 20, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$INCY
Neutral
high confidence
Mentioned
$INCY
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INCYNeutralLow
01

Why it matters

The disclosed sale amount and execution details are new, but the presence of a pre-arranged 10b5-1 plan makes it less likely to be a fresh negative fundamental signal.

02

Market read

Traders may treat this as routine insider activity with limited immediate impact on valuation, but it can be used to monitor insider behavior trends.

03

What to watch

The article does not disclose whether other insiders sold/bought around the same window, nor does it provide context on total compensation or prior sale cadence.

Relevance 3/10Novelty 3/10Timing: Filed 2026-07-20, covering a sale executed 2026-07-16.

Background

The article is an SEC Form 4 insider transaction for Incyte, reported by the CMO and Head of Late-Stage Development.

Company-level read

Ticker impact

$INCYNeutralHigh confidence
Context

Incyte Form 4 shows CMO Steven H Stein sold 1,877 shares on 2026-07-16 for about $215,348 under a 10b5-1 plan.

Expected impact

Minimal, unless follow-on filings show unusual selling outside 10b5-1 or a pattern change.

Evidence & confidence

The filing is a Form 4 insider transaction, but the article specifies the sale was under a pre-arranged 10b5-1 plan, which typically reduces interpretive signal.

Market effects

No direct sector read-across; this is company-specific insider transaction reporting.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with management de-risking ahead of catalysts, so traders may watch for clustering of similar sales.

Key entities

  • INCY

    Incyte Corporation, the subject of the Form 4 insider transaction.

  • Stein Steven H

    CMO and Head of Late-Stage Development who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

HC Wainwright & Co. reiterates Buy rating on Incyte, $152 price target

HC Wainwright & Co. reiterated a Buy rating on Incyte (INCY) with a $152 price target, suggesting a 36.5% upside from the Oct 12 close. The firm cited strong pipeline potential, particularly for drug INCB161734, with a 69% response rate in untreated patients and projected annual sales of $700 million in the U.S. G12D pancreatic cancer market.

$SNDXHighAI 8/10

Syndax shares fall as lung fibrosis drug fails trial

Syndax Pharma's shares fell 17% pre-market after abandoning its IPF drug axatilimab, which failed a phase 2 trial. The drug, partnered with Incyte, is approved for cGVHD as Niktimvo. Incyte's shares also dipped slightly. Syndax reported $152M in 2025 revenue, with $115M in the first half of 2026.

$INCYMed

Incyte (INCY) Won New Approvals, Is The Pullback A Cheap Entry?

Incyte (INCY) received U.S. approval for Atebrioz and Brazil's expedited approval for NIKTIMVO. Shares are down 6.52% in 7 days and 10.50% in 30 days, but up 11.85% year-to-date and 32.86% in 1 year. The stock trades 14% below the average analyst price target. Incyte's 2026 guidance projects total net sales of $5.13B-$5.26B and Opzelura net sales of $1.05B-$1.10B. Analysts value the stock at $128.48, while a DCF model values it at $93.58.